Exploration of Perturbed Liver Fibrosis-Related Factors and Collagen Type I in Animal Model of Non-Alcoholic Fatty Liver Disease
- PMID: 37646888
- DOI: 10.1007/s12010-023-04694-5
Exploration of Perturbed Liver Fibrosis-Related Factors and Collagen Type I in Animal Model of Non-Alcoholic Fatty Liver Disease
Abstract
To determine their involvement in the onset of the disease, we investigated the changing levels of liver fibrosis-related proteins, namely, type-I collagen, α-smooth muscle actin (α-SMA), and transforming growth factor β1 and β3 (TGF-β1, β3). The four groups of Sprague-Dawley (SD) rats were involved in the study, namely, (i) normal control group, (ii) high-fat diet group (HFD), (iii) carbon tetrachloride (CCl4) group, and (iv) NAFLD group (animal model) which were chosen at random. The NAFLD model received HFD combined with subcutaneous injection of small doses of CCl4. Histopathological examination confirmed extent of liver fibrosis, while other immunological and molecular methods were used to evaluate expression and distribution of α-SMA, type I collagen TGF-β1 and TGF-β3, at both m-RNA and protein levels. In contrast to the normal control group, the NAFLD group showed moderately elevated expressions of TGF-β1, α-SMA, and type I collagen, which was proportional on temporal scale of NAFLD persistence in the model (P < 0.05). In the early phage of NAFLD, enhancement in the mRNA transcripts and, henceforth, protein expression of TGF-β3 was observed. However, these were found to be downregulated in case of liver fibrosis (P < 0.05). This NAFLD rat model shows the histopathologic changes of human NAFLD and is suitable for the study of NAFLD pathogenesis. These findings suggest that type I collagen and the liver fibrosis-related factors TGF- β1, TGF- β3, and α-SMA may be significant contributors to NAFLD. Although NAFLD model is previously demonstrated by other researchers, our study is novel in terms of exploration of involvement of fibrosis-related factors and in particular aforementioned proteins at the early stage of NAFLD vis-à-vis dynamics of type-I collagen distribution.
Keywords: Liver fibrosis; Non-alcoholic fatty liver disease; TGF-β1; TGF-β3; α-SMA.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.PLoS One. 2013 Oct 2;8(10):e76538. doi: 10.1371/journal.pone.0076538. eCollection 2013. PLoS One. 2013. PMID: 24098525 Free PMC article.
-
High-fat diet plus carbon tetrachloride-induced liver fibrosis is alleviated by betaine treatment in rats.Int Immunopharmacol. 2016 Oct;39:199-207. doi: 10.1016/j.intimp.2016.07.028. Epub 2016 Aug 3. Int Immunopharmacol. 2016. PMID: 27494683
-
A Targeted Multiple Antigenic Peptide Vaccine Augments the Immune Response to Self TGF-β1 and Suppresses Ongoing Hepatic Fibrosis.Arch Immunol Ther Exp (Warsz). 2015 Aug;63(4):305-15. doi: 10.1007/s00005-015-0333-2. Epub 2015 Mar 5. Arch Immunol Ther Exp (Warsz). 2015. PMID: 25740471
-
Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison.Int J Mol Sci. 2024 Jul 5;25(13):7405. doi: 10.3390/ijms25137405. Int J Mol Sci. 2024. PMID: 39000518 Free PMC article. Review.
-
TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop.Exp Mol Pathol. 2022 Feb;124:104733. doi: 10.1016/j.yexmp.2021.104733. Epub 2021 Dec 13. Exp Mol Pathol. 2022. PMID: 34914973 Review.
References
-
- Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018). Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine, 97(13), e0214. https://doi.org/10.1097/MD.0000000000010214 - DOI - PubMed - PMC
-
- Sheka, A. C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P. A., & Ikramuddin, S. (2020). Nonalcoholic steatohepatitis: A review. JAMA, 323(12), 1175–1183. https://doi.org/10.1001/jama.2020.2298 - DOI - PubMed
-
- AlShaalan, R., Aljiffry, M., Al-Busafi, S., Metrakos, P., & Hassanain, M. (2015). Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 21(2), 64–70. https://doi.org/10.4103/1319-3767.153812 - DOI - PubMed
-
- Stål, P. (2015). Liver fibrosis in non-alcoholic fatty liver disease - Diagnostic challenge with prognostic significance. World journal of gastroenterology, 21(39), 11077–11087. https://doi.org/10.3748/wjg.v21.i39.11077 - DOI - PubMed - PMC
-
- Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., Hanouneh, I. A., Alhaddad, R., & Alkhouri, N. (2016). Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology international, 10(4), 632–639. https://doi.org/10.1007/s12072-015-9679-0 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical